The potential for a combined antagonism of CD47/SIRPα and PD‐1/PD‐L1 pathways is being evaluated in a Phase II study of TTI‐622 and TTI‐621 in combination with pembrolizumab for the treatment of R/R DLBCL (NCT05507541). This evidence concerns the gene CD274 and diffuse large B-cell lymphoma.